Fleischmann-Struzek, C. http://orcid.org/0000-0002-1104-3191
Mikolajetz, A.
Schwarzkopf, D.
Cohen, J.
Hartog, C. S.
Pletz, M.
Gastmeier, P.
Reinhart, K.
Funding for this research was provided by:
BMBF (FKZ: 01EO1002, 01EO1502, FKZ: 01EO1002, 01EO1502, FKZ: 01EO1002, 01EO1502, FKZ: 03ZZ0819B, FKZ: 01KI1501)
Article History
Received: 1 July 2018
Accepted: 15 September 2018
First Online: 4 October 2018
Compliance with ethical standards
:
: KR, DS and CF receive grants from the German Federal Ministry of Education and Research (BMBF) via the Center for Sepsis Control and Care (CSCC; FKZ: 01EO1002 and 01EO1502). AM receives grants from the German Federal Ministry of Education and Research (BMBF) via InfectControl2020 (FKZ: 03ZZ0819B). MP is partly supported by a grant of the Federal Ministry of Education and Research (BMBF) KliFo 2.0 (FKZ: 01KI1501). KR is unpaid chairman of the Global Sepsis Alliance. KR is a shareholder of InflaRx Jena, a University spin-off that develops adjunctive therapies for systemic inflammation and an advisor to Adrenomed Henningsdorf/Berlin, Germany, who develop an antibody against Adrenomedullin to treat cardio-circulatory shock. The remaining authors have disclosed that they do not have any potential conflicts of interest. The funding sources had no involvement in the design, analysis, and writing of the present manuscript.